Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10223971 | 0.89 | MAOB (0.43) | FDFT1CETPPPARAMAOB | |
| SCHEMBL10224002 | 0.87 | FDFT1 (0.43) | FDFT1RIPK1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1690360 | 0.86 | RIPK1 (0.51) | RIPK1ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL10223966 | 0.86 | FDFT1 (0.44) | FDFT1ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL14094667 | 0.85 | ALDH1A1 (0.49) | RIPK1ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL12866844 | 0.84 | ALDH1A1 (0.55) | FDFT1ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL12012736 | 0.83 | ESR1 (0.47) | RIPK1CACNA1BLTA4HEPHX2PPARD | |
| SCHEMBL10272415 | 0.82 | FDFT1 (0.50) | FDFT1MPOALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL17449703 | 0.82 | FFAR4 (0.41) | RIPK1ALDH1A1SMN1; SMN2MMP13LTA4H | |
| SCHEMBL9558587 | 0.82 | FFAR4 (0.41) | FDFT1MPOALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-9518000-B2 | Bicyclo [2.2.1] acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160016880-A1 | BICYCLO [2.2.1] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-7547718-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | FDFT1 3599/4885MPO 133/4885RIPK1 4634/4885 |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | FDFT1 3470/4885MPO 1879/4885RIPK1 4519/4885 |
| US-20160016880-A1 | BICYCLO [2.2.1] ACID GPR120 MODULATORS | GPR180, GPR88, GPBAR1 | FDFT1 2633/4885MPO 4811/4885RIPK1 3128/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | FDFT1 3194/4885MPO 3983/4885RIPK1 2838/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | FDFT1 4716/4885MPO 4629/4885RIPK1 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.